查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2132242

口腔黏膜藥物市場規模、佔有率和趨勢分析報告：按劑型、給藥途徑、治療應用、分銷管道、地區和細分市場預測（2026-2033 年）

Oral Transmucosal Drugs Market Size, Share & Trends Analysis Report By Dosage Form, By Route of Administration, By Therapeutic Application, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

口腔黏膜吸收藥物市場概述

預計到 2025 年，全球口服吸收藥物市場價值將達到 378 億美元，到 2026 年將成長至 405 億美元，到 2033 年將達到 685 億美元，2026 年至 2033 年的複合年成長率為 7.8%。

北美市場主導，預計到 2025 年將佔據最大的銷售佔有率，達到 38.6%。由於對用於疼痛管理、鴉片類藥物成癮、緊急癲癇治療和中樞神經系統疾病的快速起效、非侵入性藥物輸送系統的需求不斷成長，該市場正在經歷持續成長。

藥廠正日益關注舌下片、口腔膜、口腔薄膜製劑和噴霧劑等劑型，這些劑型能夠提高生物利用度，同時避免胃腸道分解和首過代謝。慢性神經系統疾病、癌症相關突發性疼痛和鴉片類藥物使用障礙在全球範圍內的日益普遍也推動了市場成長。此外，兒童和老年患者群體越來越傾向於選擇無針或無吞嚥給藥方式，這加速了這些產品在醫院和門診環境中的應用。美國、歐洲和亞洲的監管機構也透過加速核准先進的黏膜滲透製劑和專用給藥技術來支持創新。

該市場日益呈現以下特徵：製藥公司積極進行研發、平台型藥物遞送技術不斷創新以及商業化策略不斷拓展。市場參與企業正大力投資於黏膜黏附技術、滲透促進劑和先進的口腔薄膜平台，以提高藥物吸收效率和患者遵從性。隨著人們對便捷的自我給藥療法的興趣日益濃厚，用於慢性病管理和急診醫學的黏膜滲透製劑也越來越受到關注。此外，製藥公司與專業藥物遞送技術開發商之間日益密切的合作，旨在拓展獨特的製劑能力和生命週期管理策略，這也對市場產生了積極影響。數位化整合製造技術和高度擴充性的薄膜製造系統的日益普及，有助於提高生產效率、增加產品供應，並加速多個治療領域的研發管線。

隨著產業專注於研發溫度穩定的口服製劑和室溫給藥系統，市場持續成長，這些製劑提高了藥物的可及性和供應鏈的柔軟性。此外，口服胜肽類藥物傳遞、中樞神經系統（CNS）標靶治療以及新一代黏膜滲透平台的研究進展，預計將在長期內創造巨大的商業化機會。製藥公司也在增加以患者為中心的劑型的投資，以提高患者的用藥依從性並減輕給藥負擔，尤其是在老年和兒童患者中。專科藥房、電商藥品分銷管道和直接面向患者的給藥模式的日益普及，進一步提升了市場准入。此外，製劑科學和生物材料工程的不斷進步，預計將推動更有效率、更具標靶性的黏膜滲透療法的研發，從而在預測期內促進市場持續成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：口腔黏膜下給藥市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：口腔黏膜下給藥市場：以劑型進行業務分析

  • 按劑型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按劑型分類，2021-2033 年
  • 藥片
  • 電影
  • 錠劑
  • 噴
  • 貼片和凝膠

第5章：口腔黏膜下給藥市場：依給藥途徑進行業務分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 舌下給藥
  • 頰黏膜
  • 其他經由口腔粘膜給藥途徑

第6章：口腔黏膜下藥物市場：依治療應用進行業務分析

  • 按治療應用分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按治療應用分類，2021-2033年
  • 疼痛管理
  • 鴉片類成癮
  • 神經病變
  • 偏頭痛
  • 其他用途

第7章：口腔黏膜下藥物市場：依通路進行業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 口腔黏膜下給藥市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Pfizer Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Indivior PLC
    • Aquestive Therapeutics, Inc.
    • BioDelivery Sciences International（Collegium Pharmaceutical）
    • GSK plc
    • Sanofi SA
    • Novartis AG
    • Boehringer Ingelheim International GmbH
Product Code: GVR-4-68040-181-5

Oral Transmucosal Drugs Market Summary

The global oral transmucosal drugs market size was valued at USD 37.8 billion in 2025 and is projected to grow from USD 40.5 billion in 2026 to USD 68.5 billion by 2033, at a CAGR of 7.8% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 38.6% in 2025. The market is witnessing sustained expansion due to increasing demand for rapid-onset, non-invasive drug delivery systems across pain management, opioid dependence, seizure rescue therapies, and central nervous system disorders.

Pharmaceutical manufacturers are increasingly focusing on sublingual tablets, buccal films, oral thin films, and spray-based formulations that improve bioavailability while bypassing gastrointestinal degradation and first-pass metabolism. Market growth is being further supported by the rising prevalence of chronic neurological disorders, cancer-associated breakthrough pain, and opioid use disorder globally. In addition, the growing preference for needle-free and swallow-free administration among pediatric and geriatric patient populations is accelerating product adoption across both hospital and outpatient settings. Regulatory agencies in the U.S., Europe, and Asia are also supporting innovation through accelerated approvals for advanced transmucosal formulations and specialty drug delivery technologies

The market is increasingly characterized by strong research activity, platform-based drug delivery innovation, and expanding commercialization strategies among pharmaceutical companies. Industry participants are investing heavily in mucoadhesive technologies, permeation enhancers, and advanced oral film platforms to improve drug absorption efficiency and patient adherence. The growing emphasis on convenient self-administration therapies is driving interest in transmucosal delivery for chronic disease management and emergency care applications. In addition, the market is benefiting from rising collaborations between specialty drug delivery developers and pharmaceutical manufacturers aimed at expanding proprietary formulation capabilities and lifecycle management strategies. The increasing adoption of digitally integrated manufacturing technologies and scalable film production systems is also improving production efficiency, supporting broader product availability, and accelerating pipeline development across multiple therapeutic categories.

The market continues to gain momentum due to rising industry focus on temperature-stable oral formulations and ambient-storage drug delivery systems that improve accessibility and supply chain flexibility. Furthermore, growing research in oral peptide delivery, CNS-targeted therapies, and next-generation transmucosal platforms is expected to create substantial long-term commercialization opportunities. Pharmaceutical companies are also expanding investments in patient-centric dosage formats that enhance compliance and reduce administration burden, particularly among elderly and pediatric populations. The increasing penetration of specialty pharmacies, e-commerce pharmaceutical distribution channels, and direct-to-patient delivery models is further strengthening market accessibility. In addition, ongoing advancements in formulation science and biomaterial engineering are expected to support the development of more efficient and targeted transmucosal therapies, contributing to sustained market growth over the forecast period.

Global Oral Transmucosal Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral transmucosal drugs market report based on dosage form, route of administration, therapeutic application, distribution channel, and region:

  • Dosage Form Outlook (Revenue, USD Billion, 2021 - 2033)
  • Tablets
  • Films
  • Lozenges
  • Sprays
  • Patches & Gels
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Sublingual
  • Buccal
  • Other Oral Mucosal Routes
  • Therapeutic Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Pain Management
  • Opioid Dependence
  • Neurological Disorders
  • Migraine
  • Other Applications
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Dosage Form
    • 1.2.2. Route of Administration
    • 1.2.3. Therapeutic Application
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Oral Transmucosal Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Oral Transmucosal Drugs Market: Dosage Form Business Analysis

  • 4.1. Dosage Form Market Share, 2025 & 2033
  • 4.2. Dosage Form Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Billion)
  • 4.4. Tablets
    • 4.4.1. Tablets Market, 2021 - 2033 (USD Billion)
  • 4.5. Films
    • 4.5.1. Films Market, 2021 - 2033 (USD Billion)
  • 4.6. Lozenges
    • 4.6.1. Lozenges Market, 2021 - 2033 (USD Billion)
  • 4.7. Sprays
    • 4.7.1. Sprays Market, 2021 - 2033 (USD Billion)
  • 4.8. Patches & Gels
    • 4.8.1. Patches & Gels Market, 2021 - 2033 (USD Billion)

Chapter 5. Oral Transmucosal Drugs Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2025 & 2033
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
  • 5.4. Sublingual
    • 5.4.1. Sublingual Market, 2021 - 2033 (USD Billion)
  • 5.5. Buccal
    • 5.5.1. Buccal Market, 2021 - 2033 (USD Billion)
  • 5.6. Other Oral Mucosal Routes
    • 5.6.1. Other Oral Mucosal Routes Market, 2021 - 2033 (USD Billion)

Chapter 6. Oral Transmucosal Drugs Market: Therapeutic Application Business Analysis

  • 6.1. Therapeutic Application Market Share, 2025 & 2033
  • 6.2. Therapeutic Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Application, 2021 to 2033 (USD Billion)
  • 6.4. Pain Management
    • 6.4.1. Pain Management Market, 2021 - 2033 (USD Billion)
  • 6.5. Opioid Dependence
    • 6.5.1. Opioid Dependence Market, 2021 - 2033 (USD Billion)
  • 6.6. Neurological Disorders
    • 6.6.1. Neurological Disorders Market, 2021 - 2033 (USD Billion)
  • 6.7. Migraine
    • 6.7.1. Migraine Market, 2021 - 2033 (USD Billion)
  • 6.8. Other Applications
    • 6.8.1. Other Applications Market, 2021 - 2033 (USD Billion)

Chapter 7. Oral Transmucosal Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 8. Oral Transmucosal Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Oral Transmucosal Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. AbbVie Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Teva Pharmaceutical Industries Ltd.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Indivior PLC
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Aquestive Therapeutics, Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. BioDelivery Sciences International (Collegium Pharmaceutical)
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. GSK plc
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Sanofi S.A.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Novartis AG
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Boehringer Ingelheim International GmbH
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global oral transmucosal drugs market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 5 Global oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 6 Global oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 7 Global oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 8 North America oral transmucosal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 9 North America oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 10 North America oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 11 North America oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 12 North America oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 13 U.S. oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 14 U.S. oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 15 U.S. oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 16 U.S. oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Canada oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 18 Canada oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 19 Canada oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 20 Canada oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 21 Mexico oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 22 Mexico oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 23 Mexico oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 24 Mexico oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 25 Europe oral transmucosal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 26 Europe oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 27 Europe oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 28 Europe oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 29 Europe oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 UK oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 31 UK oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 32 UK oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 33 UK oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 34 Germany oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 35 Germany oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 36 Germany oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 37 Germany oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 38 France oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 39 France oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 40 France oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 41 France oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Italy oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 43 Italy oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 44 Italy oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 45 Italy oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 46 Spain oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 47 Spain oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 48 Spain oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 49 Spain oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 50 Norway oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 51 Norway oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 52 Norway oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 53 Norway oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 54 Denmark oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 55 Denmark oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 56 Denmark oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 57 Denmark oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 Sweden oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 59 Sweden oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 60 Sweden oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 61 Sweden oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific oral transmucosal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Japan oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 68 Japan oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 69 Japan oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 70 Japan oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 71 China oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 72 China oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 73 China oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 74 China oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 75 India oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 76 India oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 77 India oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 78 India oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 79 Australia oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 80 Australia oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 81 Australia oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 82 Australia oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 83 South Korea oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 84 South Korea oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 85 South Korea oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 86 South Korea oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Thailand oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 88 Thailand oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 89 Thailand oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 90 Thailand oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 91 Latin America oral transmucosal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 93 Latin America oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 94 Latin America oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 95 Latin America oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 96 Brazil oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 97 Brazil oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 98 Brazil oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 99 Brazil oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 100 Argentina oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 101 Argentina oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 102 Argentina oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 103 Argentina oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa oral transmucosal drugs market, by country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 109 South Africa oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 110 South Africa oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 111 South Africa oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 112 South Africa oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 117 UAE oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 118 UAE oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 119 UAE oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 120 UAE oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait oral transmucosal drugs market, by dosage form, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait oral transmucosal drugs market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait oral transmucosal drugs market, by therapeutic application, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait oral transmucosal drugs market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Oral transmucosal drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Oral transmucosal drugs market dynamics
  • Fig. 11 Oral transmucosal drugs market: Porter's five forces analysis
  • Fig. 12 Oral transmucosal drugs market: PESTLE analysis
  • Fig. 13 Dosage form market, 2021 - 2033 (USD Billion)
  • Fig. 14 Tablets market, 2021 - 2033 (USD Billion)
  • Fig. 15 Films market, 2021 - 2033 (USD Billion)
  • Fig. 16 Lozenges market, 2021 - 2033 (USD Billion)
  • Fig. 17 Sprays market, 2021 - 2033 (USD Billion)
  • Fig. 18 Patches & gels market, 2021 - 2033 (USD Billion)
  • Fig. 19 Route of administration market, 2021 - 2033 (USD Billion)
  • Fig. 20 Sublingual market, 2021 - 2033 (USD Billion)
  • Fig. 21 Buccal market, 2021 - 2033 (USD Billion)
  • Fig. 22 Other oral mucosal routes market, 2021 - 2033 (USD Billion)
  • Fig. 23 Therapeutic application market, 2021 - 2033 (USD Billion)
  • Fig. 24 Pain management market, 2021 - 2033 (USD Billion)
  • Fig. 25 Opioid dependence market, 2021 - 2033 (USD Billion)
  • Fig. 26 Neurological disorders market, 2021 - 2033 (USD Billion)
  • Fig. 27 Migraine market, 2021 - 2033 (USD Billion)
  • Fig. 28 Other applications market, 2021 - 2033 (USD Billion)
  • Fig. 29 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 30 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 31 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 32 Online pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 33 Oral transmucosal drugs market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 42 Europe Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 47 France country dynamics
  • Fig. 48 France Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 57 Denmark country dynamics
  • Fig. 58 Denmark Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 59 Asia Pacific Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 62 China country dynamics
  • Fig. 63 China Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 64 India country dynamics
  • Fig. 65 India Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 66 Australia country dynamics
  • Fig. 67 Australia Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 68 South Korea country dynamics
  • Fig. 69 South Korea Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 72 Latin America Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 77 MEA Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait Oral transmucosal drugs market, 2021 - 2033 (USD Billion)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework